VALPROATE SODIUM

Post-LOE

valproate sodium

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Jun 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

Drug Shortage Active

VALPROATE SODIUM is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.

VALPROATE SODIUM (valproate sodium) by Fresenius Kabi is blood. Approved for women, women of childbearing potential, epilepsy and 5 more indications. First approved in 2003.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

blood. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).

Indications (7)

women women of childbearing potential Epilepsy

Worked on VALPROATE SODIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.